The central comparison in a GWAS analysis is between genetic patterns observed in individuals with different phenotypes. Researchers may examine allele frequencies, meaning how common particular alleles are, or compare genotypes, the allele combinations carried at a locus. A statistical association test then evaluates whether these patterns differ more than expected by chance.
Population structure can create misleading associations when genetic differences between groups coincide with differences in the trait being studied. GWAS analysis therefore adjusts for this factor before interpreting a variant as relevant. This correction helps separate signals linked to population-related structure from signals more directly associated with disease susceptibility, drug response, or another measured phenotype.
GWAS analysis examines genetic variation across many genomic locations, so numerous statistical tests can produce apparently significant findings by chance alone. Adjusting for multiple comparisons makes the evidence threshold more rigorous. This step helps distinguish signals that are more likely to represent meaningful trait associations from results that arise simply because a large number of variants were tested.
An association indicates that a genetic variant or genomic region is linked statistically with a trait, but it does not by itself establish biological causation. Follow-up studies are needed to investigate whether the signal points to a causal gene or pathway. This distinction prevents researchers from treating an associated location as definitive evidence of mechanism.
A typical workflow begins by comparing genetic variation among individuals classified according to a phenotype, such as disease status or drug response. Researchers perform association tests, account for population structure, and adjust for multiple comparisons. The resulting signals are then interpreted as candidate genomic regions, with follow-up studies used to examine possible causal genes and biological pathways.
GWAS analysis can support investigations of disease susceptibility, responses to drugs, and other complex traits. Its results may identify genomic regions associated with these outcomes, providing starting points for functional research and risk prediction. When follow-up work clarifies causal genes or biological pathways, the findings can also contribute to developing targeted therapies.